What to Prepare Before Vietnam Medical Device Registration Renewal?

Published: 2026-07-10 18:08 | Updated: 2026-07-10 18:08

Focusing on international medical device registration, document preparation, compliance pathways, and post-market maintenance, this article outlines the key issues enterprises need to prioritize in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Issues
• Registration Judgment Logic
• Documents and Evidence
• Common Mistakes
• Enterprise Preparation Checklist
• AIMEILI Viewpoint
• Common Follow-up Questions
• Further Reading
• Applicability Boundary

Key Summary

Regarding "What to prepare before Vietnam medical device registration renewal," companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation basis, then evaluate technical files, quality system, labeling and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused.

Vietnam registration typically affects technical files, authorized representative, importer cooperation, labeling language, quality system certification, and subsequent change maintenance simultaneously. If the process is advanced only by "which documents to submit" in the early stage, it is easy to encounter corrections or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies plan this issue uniformly within the GHWP member states and multi-country access strategy, using a reusable core technical file to support localization in different markets, rather than temporarily redoing documents for each country.

Compiled from AIMEILI registration practice question bank, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation basis.

Applicable Scenarios and Core Issues

Companies searching for "What to prepare before Vietnam medical device registration renewal" are usually not looking for a conceptual explanation, but rather to determine whether existing documents can support Vietnam submission, whether a local agent or authorized representative is needed, why timelines may be prolonged, and which issues may affect market launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities simultaneously.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for a single country is not enough. A more valuable approach is to first create reusable versions of core technical files, quality system certification, performance verification, clinical evidence, and labeling and instructions for use, then make localized adjustments according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the intended use, mechanism of action, usage scenario, method of body contact, duration of use, whether sterile, whether active, whether containing software or IVD attributes, and then determine the risk classification and submission pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documents will deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documents. If these issues are only vaguely addressed in commercial contracts, they can easily affect market control later.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certification, technical file, performance verification report, risk management file, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer's declaration, and post-market surveillance documents.

The key to document quality is not quantity, but consistency. Claims in instructions for use, models covered by test reports, applicable scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not whether the company has uploaded many documents.

Common Mistakes

The most common problem for companies is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated domestic NMPA documents without rearranging evidence according to the Vietnam pathway.
• Too many model specifications, but insufficient coverage by test reports, clinical evidence, or labels.
• Choosing a local agent only based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistencies in claims among labels, instructions for use, promotional materials, and registration documents, leading to corrections or post-market compliance risks.
• Failure to plan multi-country document reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Enterprise Preparation Checklist

Before starting the project, it is recommended that companies use an internal checklist to confirm the documentation basis, avoiding the discovery of critical evidence gaps after entering the submission process.

• Compile a list of target products, model/specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a gap assessment table for the target country, specifying content that requires additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies do not view Vietnam registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear set of core technical files and an evidence matrix, then converting according to country requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear numerous, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for Vietnam registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to initiate a gap assessment?

It is recommended to initiate immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage product list, model specifications, registration pathway, document responsible persons, translation status, testing status, local agent communication records, and estimated submission time in the same table. This allows timely identification of document gaps and facilitates management's judgment on whether the project will affect the market launch plan.

For companies with existing registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to country requirements. In particular, labeling and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a document gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities typically focus on consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate coverage does not match the submitted product, or if the production address, model specifications, instructions for use version, and test reports are inconsistent, even if the company has prepared a large number of documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, labeling and instructions for use versions, and quality system certificates item by item. This action may seem basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously to multiple GHWP member states or with multiple product series.

Localization Conversion and Agent Responsibilities

Vietnam registration projects typically involve arrangements for local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling and instructions for use and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transportation conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest a lot of effort in obtaining the certificate but neglect post-market maintenance. Once production address changes, model expansion, instruction updates, or agent changes occur, it is easy for the certificate to become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, corrections, post-market maintenance, and renewal milestones. The value of doing so is not only to improve registration efficiency in a single country, but more importantly to enable companies to develop replicable overseas compliance capabilities and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

Previous: When is a registration change required for Vietnam medical device registration?

Next: How to group multiple models for Vietnam medical device registration submission?

Recommended Reading

• How to prepare registration documents for Malaysia medical device registration?
• How to determine product classification for Malaysia medical device registration?
• How to organize technical files for Malaysia medical device registration?
• How to localize labeling and instructions for use for Malaysia medical device registration?
• How to prepare clinical evaluation documents for Malaysia medical device registration?
• Can test reports be reused for Malaysia medical device registration?

Back to FAQ Center

News and Information

Contact AIMEILI

Content Review and Applicability Boundary

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are only used as auxiliary judgment.

Applicability Boundary: This article is for preliminary understanding, document preparation, and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.